Dissolution Testing and Metrological Measurement of Quality for Solid Oral Dosage Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dissolution Testing and Metrological Measurement of Quality for Solid Oral Dosage Forms
USP applies metrological principles to the dissolution procedure alone and in collaborative studies to understand and minimize potential sources of variability.


Pharmaceutical Technology


References

1. ISO, Guide 99: International Vocabulary of Basic and General Terms in Metrology (VIM), (Geneva, Switzerland, ISO, 2004).

2. 21 USC 351 501(a)(2)(B).

3. R. Hanson and V. Gray, Handbook of Dissolution Testing, 3rd ed. (Dissolution Technologies, Hockessin, DE, 2004).

4. US Pharmacopeial Convention, United States Pharmacopeia XIX (USP, Rockville, MD, 1975), xv–xvi.

5. Public Law 98–417 (1984).

6. G.L. Amidon et al., "A Theoretical Basis for a Biopharmaceutics Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability," Pharm. Res. 12 (3), 413–420 (1995).

7. L. Bhattacharyya et al., "The Value of USP Public Standards for Therapeutic Products," Pharm. Res. 21 (10), 1725–1731.

8. L. Buhse, "Dissolution Measurement Systems: Current State and Opportunities for Improvement," presented at FDA Advisory Committee for Pharmaceutical Science meeting, Rockville, MD, 3–4 May 2005.

9. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (2000) accessed at http://www.fda.gov/cder/guidance/3618fnl.pdf on Mar. 22, 2007.

10. WHO, Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability (2005) accessed at http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf on Mar. 22, 2007.

11. National Institute of Standards and Technology, "Guidance on Federal Conformity Assessment Activities," Fed. Regist. 65, 48894–48902 (2000).

12. FDA, Guidance for Industry: Text on Validation of Analytical Procedures (1995) accessed at http://www.fda.gov/cder/guidance/ichq2a.pdf on 26 March 2007.

13. J. Dressman and J. Kramer, Pharmaceutical Dissolution Testing (Boca Raton, FL, Taylor & Francis, 2005).

14. USP, USP 30–NF 25: Dissolution ‹711› (US Pharmacopeial Convention, Inc., Rockville, MD, 2007), 277–284.

15. ISO, Guide 5725: Accuracy (Trueness and Precision) of Measurement Methods and Results. Parts 1–6 (Geneva, Switzerland, ISO, 1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here